Dale Stafford on the State of M&A in Healthcare

Video Player is loading.

Play Video

PlaySkip BackwardSkip Forward

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

• 2x
• 1.5x
• 1x, selected
• 0.5x

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Picture-in-PictureFullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-Transparent

Text Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-TransparentTransparent

Caption Area Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDrop shadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

ResetDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

The current uncertainty surrounding the healthcare sector in the US could have adverse effects on M&A. Dale Stafford, who leads Bain's Mergers & Acquisitions practice in the Americas, appeared on Bloomberg Daybreak to discuss the opportunities for consolidation in the pharma and medtech sectors.